Clean area

Who is novosanis

Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

Colli Pee Novosanis

Improving the quality of diagnostics by volumetric self-sampling of first-void (first catch) urine

Colli-Pee postal kits for home collection

Improving the quality of home-based urine collection by easy self-sampling, alongside postal packaging

Latest news

Novosanis launches Colli-Pee containing UAS Large Volumes offering a new solution for oncology research

Novosanis launches Colli-Pee® containing UAS Large Volumes, offering a new solution for oncology research

Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS TM , for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with...

Latest blogpost

The number of scientific and peer-reviewed publications highlighting the role of first-void urine in the detection, screening, and research of HPV has increased with time. In this blog post, we recap and summarize the 2021 peer-reviewed publications that used Novosanis’ Colli-Pee® for HPV-related research.

Upcoming event

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022

Rotterdam, The Netherlands
Novosanis will be attending the Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022 conference on March 1 & 2. The conference will focus on the development of liquid biopsies utilizing circulating cell-free DNA (cfDNA), circulating tumour cells (CTCs) and other biomarkers found in...